Solvay Patent-Cliff Exposure & CMS Drug Spending Portfolio

Solvay (US): 1 reconciled FDA prescription therapies, $73.6M 2024 CMS Part D & Medicaid spend, and 17 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$73.6M
2024 Medicare Part D Spend$60.5M
2024 Medicaid Spend$13.2M
California HCAI SB 17 Filings17 WAC filings (max 167.3% 2-yr change)